Opus Genetics Inc Ordinary Shares IRD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
-
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
-
Opus Genetics to Present at the Chardan Annual Healthcare Conference
-
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
-
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
-
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
-
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Trading Information
- Previous Close Price
- $4.05
- Day Range
- $3.75–4.13
- 52-Week Range
- $1.70–7.07
- Bid/Ask
- $3.77 / $3.82
- Shares Outstanding
- 83.20M
- Market Cap
- $319.47M
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 35.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.opusgtx.com
Valuation
|
Metric
|
IRD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 35.91 |
Price/Cash Flow | — |
Price/Earnings
IRD
Financial Strength
|
Metric
|
IRD
|
|---|---|
Quick Ratio | 11.87 |
Current Ratio | 12.19 |
Interest Coverage | −40.73 |
Quick Ratio
IRD
Profitability
|
Metric
|
IRD
|
|---|---|
Return on Assets (Normalized) | −76.76% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,000.32% |
Return on Assets
IRD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%G^H&$ | LOCK|gtP$ | $127B | |||
| Moderna Inc
MRNA
| LOCK|N%GL$! | LOCK|%P? | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|qt^HGz | LOCK|#&Gj | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>$?>qY | LOCK|&c | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Y@m>T%x | LOCK|?CD | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Jfl&pP | LOCK|vVKN | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<v^#<#% | LOCK|!zTbj | $27B | |||
| Incyte Corp
INCY
| LOCK|x^>>%DD | LOCK|$p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|rPy@CC | LOCK|?h | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&LWGw& | LOCK|SCl | $14B |
United States